Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 12/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3723956 | 0.89 | HTR6 (0.44) | HTR6CYP2C19PKMDRD2HTR2A | |
| SCHEMBL3721496 | 0.86 | HTR6 (0.45) | HTR6CYP2C19DRD2HTR2AMET | |
| SCHEMBL19654939 | 0.84 | CYP2C19 (0.49) | HTR6CYP2C19PKMDRD2HTR2A | |
| SCHEMBL12425664 | 0.83 | CYP2C19 (0.48) | HTR6CYP2C19PKMDRD2HTR2A | |
| SCHEMBL30134883 | 0.83 | CYP2C19 (0.48) | HTR6CYP2C19PKMDRD2HTR2A | |
| SCHEMBL3723254 | 0.83 | CYP2C19 (0.48) | HTR6CYP2C19PKMDRD2HTR2A | |
| SCHEMBL1469143 | 0.83 | CYP2C19 (0.48) | HTR6CYP2C19PKMDRD2HTR2A | |
| SCHEMBL16041786 | 0.83 | CYP2C19 (0.48) | HTR6CYP2C19PKMDRD2HTR2A | |
| SCHEMBL27821419 | 0.82 | HTR6 (0.52) | HTR6CYP2C19PKMDRD2HTR2A | |
| SCHEMBL1134990 | 0.81 | CYP2C19 (0.46) | HTR6CYP2C19PKMDRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841304-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140221370-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-08-07 | — | — | US | disclosed |
| CN-101959887-B | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC | 2013-07-31 | — | — | CN | disclosed |
| EP-2242755-B1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-09-12 | — | — | EP | disclosed |
| CN-101959887-A | Pyrrolopyridine as kinase inhibitor | ARRAY BIOPHARMA INC | 2011-01-26 | — | — | CN | disclosed |
| US-20100324041-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2242755-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009089352-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221370-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | HTR6 4510/4885CYP2C19 3656/4885PKM 322/4885 |
| US-20100324041-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | HTR6 4472/4885CYP2C19 3557/4885PKM 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.